Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06544265 · ClinicalTrials.gov registry record · Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL

A Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Verismo Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
5
Study locations

NCT06544265 is a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Verismo Therapeutics. The registered enrollment target is 18 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06544265, a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Verismo Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
5
Study locations

Study Summary

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Conditions Studied

Mantle Cell Lymphoma Follicular Lymphoma Marginal Zone Lymphoma B-cell Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma DLBCL - Diffuse Large B Cell Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma Aggressive B-Cell Non-Hodgkin Lymphoma NHL, Adult

Interventions

  • BIOLOGICAL SynKIR-310

Study Locations (5)

Colorado

  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute - Denver

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Kansas

  • The University of Kansas Cancer Center - Fairway

New Jersey

  • Rutgers Cancer Institute - New Brunswick

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2024-11-01
Est. Completion 2028-12
Phase Phase 1

Sponsor

Verismo Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06544265

The ClinicalTrials.gov registry entry for NCT06544265 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Verismo Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SynKIR-310 is the first listed.

NCT06544265 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Georgia, Kansas.

Frequently Asked Questions

What is clinical trial NCT06544265 about?

NCT06544265 is a clinical study titled "SynKIR-310 for Relapsed/Refractory B-NHL". This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

What is the current status of trial NCT06544265?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-11-01. Estimated completion is 2028-12.

What conditions does trial NCT06544265 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT06544265?

The interventions under investigation include: SynKIR-310 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06544265?

This trial is sponsored by Verismo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06544265 being conducted?

This trial has 5 study locations across Colorado, Georgia, Kansas, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

Follicular Lymphoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.